Danaher (DHR) Stock Forecast & Price Target

$174.71 +0.08 (+0.05%)

As of 02:42 PM Eastern

Compare

Danaher - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
3

Buy
18

Based on 21 Wall Street analysts who have issued ratings for Danaher in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 3 have given a hold rating, and 18 have given a buy rating for DHR.

Consensus Price Target

$240.70
37.77% Upside

According to the 21 analysts' twelve-month price targets for Danaher, the average price target is $240.70. The highest price target for DHR is $275.00, while the lowest price target for DHR is $205.00. The average price target represents a forecasted upside of 37.77% from the current price of $174.71.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for DHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Danaher and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DHR Analyst Ratings Over Time

Type	Current Forecast 5/6/25 to 5/6/26	1 Month Ago 4/6/25 to 4/6/26	3 Months Ago 2/5/25 to 2/5/26	1 Year Ago 5/6/24 to 5/6/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	19 Buy rating(s)	20 Buy rating(s)	16 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$240.70	$252.10	$253.86	$248.77
Forecasted Upside	37.77% Upside	31.26% Upside	17.69% Upside	30.86% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

DHR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Danaher Stock vs. The Competition

Type	Danaher	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	37.79% Upside	938.13% Upside	14.77% Upside
News Sentiment Rating	Positive News See Recent DHR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/24/2026	Argus 3 of 5 stars		Lower Target	Buy	$265.00 ➝ $230.00	+29.72%
4/22/2026	Morgan Stanley 3 of 5 stars	Kallum Titchmarsh Not Rated	Lower Target	Overweight	$270.00 ➝ $255.00	+38.50%
4/22/2026	UBS Group 4 of 5 stars	Dan Leonard 4 of 5 stars	Lower Target	Buy	$270.00 ➝ $250.00	+35.79%
4/22/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Overweight	$275.00 ➝ $245.00	+25.95%
4/22/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Couillard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$240.00 ➝ $212.00	+8.98%
4/22/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$245.00 ➝ $240.00	+23.38%
4/22/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Subbu Nambi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$275.00 ➝ $235.00	+20.81%
4/21/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$245.00	+25.80%
4/21/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$225.00 ➝ $232.00	+19.27%
4/17/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Catherine Ramsey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$251.00 ➝ $249.00	+28.76%

4/17/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$205.00	+6.01%
4/14/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$250.00 ➝ $230.00	+17.38%
4/13/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evie Koslosky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$265.00 ➝ $230.00	+18.28%
4/8/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$260.00 ➝ $230.00	+20.40%
3/27/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
1/29/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
1/29/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
1/16/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$260.00 ➝ $270.00	+14.38%
12/1/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$255.00 ➝ $270.00	+18.95%
9/22/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derik De Bruin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$230.00 ➝ $220.00	+15.24%
9/2/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$241.00	+18.26%
7/11/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sung Ji Nam Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$275.00	+33.79%
4/7/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
3/14/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$260.00	+27.48%
2/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Cooper Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
10/23/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$315.00 ➝ $315.00	+23.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:39 PM ET.

Should I Buy Danaher Stock? DHR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 30, 2026. Please send any questions or comments about these Danaher pros and cons to contact@marketbeat.com.

Danaher
Bull Case

Here are some ways that investors could benefit from investing in Danaher Co.:

The current stock price is around $179, which may present a buying opportunity for investors looking for growth in the science and technology sector.
Danaher Co. has recently increased its quarterly dividend from $0.32 to $0.40, indicating a commitment to returning value to shareholders and reflecting strong financial health.
Analysts anticipate that Danaher Co. will post earnings per share (EPS) of approximately 8.43 for the current fiscal year, suggesting robust profitability and growth potential.
The company has a solid market capitalization of approximately $126.85 billion, which positions it as a significant player in the life sciences and diagnostics markets.
Danaher Co. has a diverse portfolio across various segments, including Life Sciences and Diagnostics, which helps mitigate risks associated with market fluctuations.

Danaher
Bear Case

Investors should be bearish about investing in Danaher Co. for these reasons:

The stock has experienced volatility, with a 1-year high of $242.80 and a low of $175.00, indicating potential risks for investors concerned about price fluctuations.
Danaher Co. has a relatively high price-to-earnings (P/E) ratio of 34.67, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
Insider transactions have shown a decrease in ownership, with executives selling shares, which could raise concerns about their confidence in the company's future performance.
The company has a debt-to-equity ratio of 0.33, which, while manageable, indicates that it does carry some debt, potentially affecting its financial flexibility.
With 79.05% of the stock owned by hedge funds and institutional investors, retail investors may find it challenging to influence company decisions or stock performance.

DHR Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Danaher is $240.70, with a high forecast of $275.00 and a low forecast of $205.00.
: 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 3 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DHR shares.
: According to analysts, Danaher's stock has a predicted upside of 37.77% based on their 12-month stock forecasts.
: Danaher has been rated by research analysts at Argus, Barclays, Evercore, Guggenheim, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Rothschild & Co Redburn, TD Cowen, The Goldman Sachs Group, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Danaher more than other "medical" companies. The consensus rating for Danaher is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how DHR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Danaher Recommendations

This page (NYSE:DHR) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Danaher (DHR) Stock Forecast & Price Target

Danaher - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

DHR Analyst Ratings Over Time

DHR Analyst Recommendations By Month

DHR Price Targets by Month

Danaher Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Danaher Stock? DHR Pros and Cons Explained

Danaher
Bull Case

Danaher
Bear Case

DHR Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Danaher Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Danaher (DHR) Stock Forecast & Price Target

Danaher - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

DHR Analyst Ratings Over Time

DHR Analyst Recommendations By Month

DHR Price Targets by Month

Danaher Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Danaher Stock? DHR Pros and Cons Explained

Danaher Bull Case

Danaher Bear Case

DHR Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Danaher Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Danaher
Bull Case

Danaher
Bear Case